


The role of nuclear export in TDP43-mediated neurodegeneration


Hilary C. Archbold¹, Sharon Tamir², Xingli Li¹, Sami J. Barmada¹

¹Department of Neurology, University of Michigan, Ann Arbor, MI; ²Karyopharm Therapeutics, Newton, MA; ³Cellular & Molecular Biology Program, ⁴Neuroscience Program, University of Michigan, Ann Arbor, MI


Cytoplasmic TDP43 mislocalization is found in the related neurodegenerative diseases ALS and FTD




Longitudinal Fluorescence Microscopy: tracking neuronal survival in a model of ALS/FTD




Live imaging of exogenous TDP43 kinetics in response to SINE compounds shows no change in subcellular localization




SINE compounds are broadly neuroprotective




Exportin1 is a candidate transporter for TDP43




SINE compounds are neuroprotective in a neuronal model of ALS and FTD




How do SINE compounds exert their protective effect?




Selective inhibitor of nuclear export (SINE) compounds



SINE compounds do not appear to alter the subcellular localization of endogenous TDP43



SINE compounds and transcriptional regulation



Acknowledgements

The Barmada Lab:
Sami Barmada, MD, PhD
Elizabeth Tank, PhD
Xingli Li, MD
Roberto Miguez
Brittany Flores
Kate Weskamp
Nathaniel Safren, PhD
Alex Bennett

UM Neurology Dept:
Denise Hecker, Howard Oishi
The Feldman, Shakktoui, Zou, Todd, Paulson, Daurer, and Parent Labs

LSU:
Klein Lab

Karyopharm Therapeutics, Inc.

Postdoctoral training committee:
Sami Barmada, MD, PhD
Peter Todd MD, PhD
Aaron Goldstrom, PhD

Funding:
The ALS Therapy Alliance
NIH NINDS 1K08NS072233-01A1
Association for Frontotemporal Degeneration
UM Dept of Neurology Training Grant 5T32NS007222-33

